1998

Troglitazone Reduces LDL Oxidation and Lowers Plasma E-Selectin Concentration in NIDDM Patients

Top

Cominacini L, Garbin U, Pasini AF, et al. Diabetes Troglitazone Reduces LDL Oxidation and Lowers Plasma E-Selectin Concentration in NIDDM Patients.  Diabetes. 1998;47:130-133. Troglitazone, an oral antidiabetic agent with antioxidant properties, has previously been shown to increase the resistance of LDL to oxidation in vitro and in vivo in healthy volunteers.

Troglitazone in Combination With Sulfonylurea Restores Glycemic Control in Patients With Type 2 Diabetes

Top

Horton ES, et al. Troglitazone in Combination With Sulfonylurea Restores Glycemic Control in Patients With Type 2 Diabetes. Diabetes Care. 1998;21:1462-1469. To determine if the combination of troglitazone (a peroxisome proliferator-activated receptor- activator) and sulfonylurea will provide efficacy not attainable by either medication alone.

Troglitazone Decreases the Proportion of Small, Dense LDL and Increases the Resistance of LDL to Oxidation in Obese Subjects

Top

Demacker PNM, Smits P, Stalenhoef AFH, Tack CJJ. Dense LDL and Increases the Resistance of LDL to Oxidation in Obese Subjects.  Diabetes Care. 1998;21:796-799. Insulin resistance is associated with a predominance of small, atherogenic LDL particles that are more prone to oxidative modification. Treatment with the insulin-sensitizer troglitazone may improve LDL composition and resistance to oxidation.

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

Top

UK Prospective Diabetes Study (UKPDS) Group. Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 38. BMJ. 1998;317:703-713. To determine whether tight control of blood pressure prevents macrovascular and microvascular complications in patients with type 2 diabetes.

The Effects of Improved Glycemic Control on Complications in Type 2 Diabetes

Top

Gaster B, Hirsch IB. The Effects of Improved Glycemic Control on Complications in Type 2 Diabetes. Ann Intern Med. 1998;158:134-140. Type 2 diabetes is 8 to 10 times more common than type 1 diabetes, but no single large trial has established that improved glycemic control can prevent complications in type 2 diabetes.

Stress Hyperglycaemia and Increased Risk of Death After Myocardial Infarction in Patients With and Without Diabetes: A Systematic Overview

Top

Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress Hyperglycaemia and Increased Risk of Death After Myocardial Infarction in Patients With and Without Diabetes: A Systematic Overview. Lancet. 2000;355:773-778. High blood glucose concentration may increase risk of death and poor outcome after acute myocardial infarction (MI). We did a systematic review and meta-analysis to assess the risk of in-hospital mortality or congestive heart failure (CHF) after MI in patients with and without diabetes who had stress hyperglycemia on admission.

Prevalence of Insulin Resistance in Metabolic Disorders: The Bruneck Study

Top

Bonora E, Kiechl S, Willeit J, et al. Prevalence of Insulin Resistance in Metabolic Disorders: The Bruneck Study. Diabetes. 1998;47:1643-1649. The prevalence of insulin resistance in the most common metabolic disorders is still an undefined issue. We assessed the prevalence rates of insulin resistance in subjects with impaired glucose tolerance (IGT), NIDDM, dyslipidemia, hyperuricemia, and hypertension as identified within the frame of the Bruneck Study.

Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults

Top

Harris MI, Flegal KM, Cowie CC, et al. Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults The Third National Health and Nutrition Examination Survey, 1988-1994.  Diabetes Care. 1998;21:518-524. To evaluate the prevalence and time trends for diagnosed and undiagnosed diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults by age, sex, and race or ethnic group, based on data from the Third National Health and Nutrition Examination Survey, 1988-1994 (NHANES III) and prior Health and Nutrition Examination Surveys (HANESs).

Multiple Metabolic Syndrome Is Associated With Lower Heart Rate Variability: The Atherosclerosis Risk in Communities Study

Top

Liao D, Sloan RP, Cascio WE, et al. Multiple Metabolic Syndrome Is Associated With Lower Heart Rate Variability: The Atherosclerosis Risk in Communities Study.  Diabetes Care. 1998;21:2116-2122. To test at the population level whether people with multiple metabolic syndrome (MMS) disorders have reduced cardiac autonomic activity (CAA).

Microalbuminuria is Associated With Insulin Resistance in Nondiabetic Subjects: The Insulin Resistance Atherosclerosis Study

Top

Mykkänen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is Associated With Insulin Resistance in Nondiabetic Subjects: The Insulin Resistance Atherosclerosis Study. Diabetes. 1998;47:793-800. Microalbuminuria is associated with excess cardiovascular mortality in both diabetic and nondiabetic subjects. Patients with NIDDM and microalbuminuria are more insulin resistant than those without microalbuminuria.

1 2 Next